TTTY18: TTTY18 is a long noncoding RNA (lncRNA) that has been implicated in various biological processes, including cancer. In a study, three different congeners (BDE-47, BDE-99, and BDE-209) were found to induce seven differentially expressed lncRNAs (DELs), including TTTY18 [PMC9697228]. Another study showed that genistein (GEN), a compound with anticancer properties, downregulated TTTY18 expression and inhibited the TTTY18/AKT pathway in colorectal cancer (CRC) cells [PMC9774417]. In vitro experiments with genistein-dosed CRC cells demonstrated reduced cell viability, increased cell death, decreased cell migration, and downregulated levels of SGK1, TTTY18, AktSer473, and p38 MAPKTyr323 [PMC9259214]. Furthermore, CRC cases showed elevated levels of TTTY18 expression along with increased expressions of transforming growth factor beta-1 (TGF-1), serum and glucocorticoid regulated kinase-1 (SGK1), Ki-67, and Akt-Ser473 [PMC9259214]. In an in vivo investigation using genistein-dosed tumor-bearing nude mice, decreased tumorous concentrations of TGF-1 and TTTY18 were observed along with reduced body mass [PMC9259214]. Additionally, the UTY and CYG2P1 genes exhibited changes in the CG intron site while SPRY3 and TTTY18 showed no obvious changes [PMC10083376]. These findings highlight the involvement of TTTY18 in cancer development and its potential as a therapeutic target.